Aesica plans global expansion with debt
This article was originally published in Scrip
Private equity group Silverfleet Capital has acquired a majority position in Aesica Pharmaceuticals ,,the UK-headquartered contract pharmaceutical formulator and manufacturer, by buying the stake owned by LDC, the private equity arm of Lloyds Bank. Members of Aesica's executive team have also agreed to reinvest a significant amount to secure a large minority stake. Debt, provided by Lloyds, HSBC and Yorkshire Bank, will be used to underwrite the company's international expansion ambitions, particularly in the US.
You may also be interested in...
Cambridge, UK-based Healx has concluded a $56m series B round, led by Atomico, to put up to 50 potential rare disease treatments into the clinic within two years using its AI/ML platform.
Tapping into the ability of arenaviruses to deliver prolonged local immune activation, rapid regression of localized and metastatic cancers, and long-term disease control, Essen, Germany-based start-up Abalos Therapeutics has raised €12m to advance its lead candidates towards clinical testing.
Celgene agrees to pay $75m upfront for options to three Immatics TCR-T targets for solid tumors. Deal could be worth up to $1.59bn to the German biotech, which also retains option to co-develop and co-fund certain licensed products.